U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H18N3O5S.Na
Molecular Weight 387.386
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMOXICILLIN SODIUM

SMILES

[Na+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C3=CC=C(O)C=C3)C([O-])=O

InChI

InChIKey=BYHDFCISJXIVBV-YWUHCJSESA-M
InChI=1S/C16H19N3O5S.Na/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);/q;+1/p-1/t9-,10-,11+,14-;/m1./s1

HIDE SMILES / InChI

Molecular Formula C16H18N3O5S
Molecular Weight 364.396
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Amoxicillin is one of the widely prescribed antibacterial agents, which was discovered by scientists at Beecham Research Laboratories in 1972. In the US GlaxoSmithKline markets it under the original brand name Amoxil. It is the first line treatment for middle ear infections. It is also used for strep throat, pneumonia, skin infections, and urinary tract infections it is taken by mouth. Amoxicillin inhibits the third and final stage of bacterial cell wall synthesis by preferentially binding to specific penicillin-binding proteins (PBPs) that are located inside the bacterial cell wall. This results in a formation of defective cell wall and a cell death. Common side effects include nausea and rash. It may also increase the risk of yeast infections and, when used in combination with clavulanic acid, diarrhea. It should not be used in those who are allergic to penicillin.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Curative
AMOXIL

Approved Use

AMOXICILLIN is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose and throat - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract - due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure - due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract - due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) - due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple Therapy: AMOXICILLIN/clarithromycin/lansoprazole AMOXICILLIN, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradiate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) Dual Therapy: AMOXICILLIN/lansoprazole AMOXICILLIN, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H.pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H.pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION.) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AMOXICILLIN and other antibacterial drugs, AMOXICILLIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed.

Launch Date

3.40934394E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
11.8 μg/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
37.6 μg × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.5 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
AMOXICILLIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Disc. AE: Pharyngolaryngeal pain...
Other AEs: Nausea, Pharyngotonsillitis...
AEs leading to
discontinuation/dose reduction:
Pharyngolaryngeal pain (severe, 0.6%)
Other AEs:
Nausea (1.5%)
Pharyngotonsillitis (0.9%)
Vulvovaginal candidiasis (0.9%)
Headache (0.7%)
Diarrhea (0.5%)
Abdominal pain (0.5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Diarrhea 0.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Headache 0.7%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Pharyngotonsillitis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Vulvovaginal candidiasis 0.9%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Nausea 1.5%
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Pharyngolaryngeal pain severe, 0.6%
Disc. AE
775 mg 1 times / day steady, oral
Dose: 775 mg, 1 times / day
Route: oral
Route: steady
Dose: 775 mg, 1 times / day
Sources:
unhealthy, > 12 years
n = 302
Health Status: unhealthy
Condition: pharyngitis secondary to Streptococcus pyogenes
Age Group: > 12 years
Population Size: 302
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Cerebral and renal toxicity of acyclovir in a patient treated for meningoencephalitis].
1999 Nov
[Acute renal failure after amoxicillin crystallization].
2000 Apr 8
Omeprazole-induced delirium.
2000 Jan
[Intrahepatic cholestasis induced by amoxicillin alone].
2000 May
Use of antibiotics to treat bacteriuria of pregnancy in the Nordic countries. Which antibiotics are appropriate to treat bacteriuria of pregnancy?
2001 Apr
A prospective observational study of 5-, 7-, and 10-day antibiotic treatment for acute otitis media.
2001 Apr
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.
2001 Apr
Efficacy, safety and tolerability of 3 day azithromycin versus 10 day co-amoxiclav in the treatment of children with acute lower respiratory tract infections.
2001 Apr
Effects of lansoprazole, clarithromycin and pH gradient on uptake of [14C]amoxycillin into rat gastric tissue.
2001 Apr
Helicobacter eradication versus prompt endoscopy for dyspepsia.
2001 Apr
Simultaneous determination of five beta-lactam antibiotics in bovine milk using liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
2001 Apr 1
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.
2001 Apr 1
Comparison of amoxicillin and azithromycin in the prevention of recurrent acute otitis media.
2001 Apr 6
Management of brain stem abscess.
2001 Feb
Spectrophotometric determination of ampicillin, dicluxacillin, flucloxacillin and amoxicillin antibiotic drugs: ion-pair formation with molybdenum and thiocyanate.
2001 Feb
Bioequivalence study of a novel Solutab tablet formulation of amoxicillin/clavulanic acid versus the originator film-coated tablet.
2001 Feb
Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
2001 Feb
Comparison of the efficacy and safety of different formulations of omeprazole-based triple therapies in the treatment of Helicobacter pylori-positive peptic ulcer.
2001 Feb
Acute generalized exanthematous pustulosis induced by amoxycillin with clavulanate.
2001 Feb
Erythema-multiforme-like eruption from amoxycillin and allopurinol.
2001 Feb
Topical antibiotic prophylaxis for bacteremia after dental extractions.
2001 Feb
Clostridium difficile--Associated diarrhea: A review.
2001 Feb 26
Improved phagocyte response by co-amoxiclav in renal transplant recipients.
2001 Feb 27
[Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities?].
2001 Jan
[Pneumococcal antibiotic resistance. Results from 21 regional registries for 1999].
2001 Jan
[Pneumococcal antibiotic resistance in 1999. Results from 19 registries for 1999].
2001 Jan
[Prevention of endocarditis within the scope of ENT interventions. Current recommendations].
2001 Jan
Potential for milk containing penicillin G or amoxicillin to cause residues in calves.
2001 Jan
Necrotizing meningoencephalitis associated with cortical hippocampal hamartia in a Pekingese dog.
2001 Jan
Compliance issues related to the selection of antibiotic suspensions for children.
2001 Jan
Randomized, double-blind, double-dummy study comparing the efficacy and safety of amoxycillin 1 g bd with amoxycillin 500 mg tds in the treatment of acute exacerbations of chronic bronchitis.
2001 Jan
A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China.
2001 Jan
[Prevalence of Moraxella catarrhalis colonization in asymptomatic carriers under 6 years of age].
2001 Jan-Feb
Charm Safe-Level beta-Lactam Test for amoxicillin, ampicillin, ceftiofur, cephapirin, and penicillin G in raw commingled milk.
2001 Jan-Feb
Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
2001 Jan-Feb
[A prospective study on erysipelas and infectious cellulitis: how are they dealt within hospital?].
2001 Mar
Peptic ulcer occurrence in follow-up of chronic gastritis in patients with treated and not eradicated CagA-positive Helicobacter pylori infection.
2001 Mar
Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998.
2001 Mar
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
2001 Mar
Screening method for identification of beta-lactams in bovine urine by use of liquid chromatography and a microbial inhibition test.
2001 Mar
A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication.
2001 Mar
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
2001 Mar
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
2001 Mar
[Angina tonsillaris in children. Penicillin V can not be recommended here].
2001 Mar 22
Simultaneous determination of amoxycillin and clavulanic acid in pharmaceutical dosage forms by LC with amperometric detection.
2001 May
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999.
2001 May 15
Prospective evaluation of the impact of amoxicillin, clarithromycin and their combination on human gastrointestinal colonization by Candida species.
2001 May-Jun
Patents

Sample Use Guides

In adults, 750-1750 mg/day in divided doses every 8-12 hours. In Pediatric Patients > 3 Months of Age, 20-45 mg/kg/day in divided doses every 8-12 hours. Treatment of gonorrhea is 3 grams as a single oral dose. The upper dose for neonates and infants ≤ 3 months is 30 mg/kg/day divided every 12 hours. Dosing for H. pylori Infection: Triple therapy: 1 gram AMOXIL, 500 mg clarithromycin, and 30 mg lansoprazole, all given twice daily (every 12 hours) for 14 days. Dual therapy: 1 gram AMOXIL and 30 mg lansoprazole, each given three times daily (every 8 hours) for 14 days.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:02:55 UTC 2023
Edited
by admin
on Wed Jul 05 23:02:55 UTC 2023
Record UNII
544Y3D6MYH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMOXICILLIN SODIUM
EP   MART.   USAN   WHO-DD  
USAN  
Official Name English
Amoxicillin sodium [WHO-DD]
Common Name English
BRL-2333AB-B
Code English
Amoxicillin (as the sodium salt)
Common Name English
AMOXICILLIN SODIUM SALT [MI]
Common Name English
AMOXICILLIN SODIUM [MART.]
Common Name English
SODIUM AMOXICILLIN
Common Name English
AMOXICILLIN SODIUM SALT
MI  
Common Name English
AMOXICILLIN SODIUM [EP MONOGRAPH]
Common Name English
AMOXICILLIN SODIUM [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1500
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
Code System Code Type Description
MERCK INDEX
M1844
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1082
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
USAN
KK-95
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
EPA CompTox
DTXSID80956137
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
CAS
34642-77-8
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
SMS_ID
100000090113
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
ECHA (EC/EINECS)
252-124-1
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
FDA UNII
544Y3D6MYH
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
EVMPD
SUB00503MIG
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
PUBCHEM
23663126
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
NCI_THESAURUS
C72700
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
CHEBI
51255
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
DRUG BANK
DBSALT000868
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
DAILYMED
544Y3D6MYH
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY
RXCUI
267360
Created by admin on Wed Jul 05 23:02:55 UTC 2023 , Edited by admin on Wed Jul 05 23:02:55 UTC 2023
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY